Drug Prices

The House Energy and Commerce Health Subcommittee held a hearing on improving drug pricing transparency and lowering prices for…

The Centers for Medicare and Medicaid Services (“CMS”) announced a final rule permitting Medicare Part B plans, including those…

We have previously written about the law in Nevada requiring reporting for pharmaceutical representatives and the law that…

On April 4-5, 2019, the Medicare Payment Advisory Committee (“MedPAC”) held a public meeting in Washington, DC to discuss issues…

The Health Resources & Services Administration (“HRSA”) Office of Pharmacy Affairs recently launched an online tool that…

The Massachusetts law that permits the use of pharmaceutical manufacturer drug coupons is on life support. The law was set to…

On March 28, 2019, the Federal Trade Commission (“FTC”) issued an Opinion and Final Order against Impax Laboratories LLC…

Here in the US, there has been a tremendous amount of discussion in recent years about the soaring cost of prescription drugs, and…

On April 18, 2019, President Trump signed H.R. 1839—Medicaid Services Investment and Accountability Act of 2019—into law.  The new…

Oklahoma’s experimental Medicaid program is increasingly seen as a warning for the proponents of value-based pharmaceutical…